GB1560247A - Pharmaceutical compositions - Google Patents
Pharmaceutical compositions Download PDFInfo
- Publication number
- GB1560247A GB1560247A GB51442/77A GB5144277A GB1560247A GB 1560247 A GB1560247 A GB 1560247A GB 51442/77 A GB51442/77 A GB 51442/77A GB 5144277 A GB5144277 A GB 5144277A GB 1560247 A GB1560247 A GB 1560247A
- Authority
- GB
- United Kingdom
- Prior art keywords
- phenoxypyridine
- composition according
- pharmaceutically acceptable
- monosulfate
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000008194 pharmaceutical composition Substances 0.000 title description 3
- KDGUIKPOZGYLQJ-UHFFFAOYSA-N 3-phenoxypyridine Chemical compound C=1C=CN=CC=1OC1=CC=CC=C1 KDGUIKPOZGYLQJ-UHFFFAOYSA-N 0.000 claims description 43
- 239000000203 mixture Substances 0.000 claims description 34
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 19
- 239000002775 capsule Substances 0.000 claims description 14
- 235000019359 magnesium stearate Nutrition 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 5
- 239000007903 gelatin capsule Substances 0.000 claims description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
- 239000008203 oral pharmaceutical composition Substances 0.000 claims description 3
- 229920001817 Agar Polymers 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 2
- 229910002651 NO3 Inorganic materials 0.000 claims description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- 239000008272 agar Substances 0.000 claims description 2
- 239000000783 alginic acid Substances 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 229960001126 alginic acid Drugs 0.000 claims description 2
- 150000004781 alginic acids Chemical class 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 229940018560 citraconate Drugs 0.000 claims description 2
- HNEGQIOMVPPMNR-IHWYPQMZSA-N citraconic acid Chemical compound OC(=O)C(/C)=C\C(O)=O HNEGQIOMVPPMNR-IHWYPQMZSA-N 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 235000000346 sugar Nutrition 0.000 claims description 2
- 239000000454 talc Substances 0.000 claims description 2
- 229910052623 talc Inorganic materials 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 2
- 239000008158 vegetable oil Substances 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 claims 1
- 229940040563 agaric acid Drugs 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 235000012222 talc Nutrition 0.000 claims 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 1
- JTIUHKZUVGVPGO-UHFFFAOYSA-N [3-[(4-bromophenyl)carbamoyl]phenyl]boronic acid Chemical compound OB(O)C1=CC=CC(C(=O)NC=2C=CC(Br)=CC=2)=C1 JTIUHKZUVGVPGO-UHFFFAOYSA-N 0.000 description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 19
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 18
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 16
- 239000008101 lactose Substances 0.000 description 16
- 239000000243 solution Substances 0.000 description 13
- 239000003826 tablet Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 229920002261 Corn starch Polymers 0.000 description 7
- 239000008120 corn starch Substances 0.000 description 7
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 6
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 6
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 6
- 229960004592 isopropanol Drugs 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 208000020401 Depressive disease Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000001914 calming effect Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 201000003102 mental depression Diseases 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000005550 wet granulation Methods 0.000 description 3
- SDQRZXYVRDMNAS-UHFFFAOYSA-N 3-phenoxypyridine;hydrobromide Chemical compound Br.C=1C=CN=CC=1OC1=CC=CC=C1 SDQRZXYVRDMNAS-UHFFFAOYSA-N 0.000 description 2
- ANLSFFWTJMLWDA-UHFFFAOYSA-N 3-phenoxypyridine;hydrochloride Chemical compound Cl.C=1C=CN=CC=1OC1=CC=CC=C1 ANLSFFWTJMLWDA-UHFFFAOYSA-N 0.000 description 2
- FWYPEGDVPXQSGI-UHFFFAOYSA-N 4-methylbenzenesulfonic acid;3-phenoxypyridine Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.C=1C=CN=CC=1OC1=CC=CC=C1 FWYPEGDVPXQSGI-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 208000019914 Mental Fatigue Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- KHNFQENNQVFLDW-UHFFFAOYSA-N methanesulfonic acid;3-phenoxypyridine Chemical compound CS(O)(=O)=O.C=1C=CN=CC=1OC1=CC=CC=C1 KHNFQENNQVFLDW-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- FBXWPIWRAQEKDI-UHFFFAOYSA-N nitric acid;3-phenoxypyridine Chemical compound O[N+]([O-])=O.C=1C=CN=CC=1OC1=CC=CC=C1 FBXWPIWRAQEKDI-UHFFFAOYSA-N 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 206010048909 Boredom Diseases 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 102000010909 Monoamine Oxidase Human genes 0.000 description 1
- 108010062431 Monoamine oxidase Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 240000006474 Theobroma bicolor Species 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000001761 ethyl methyl cellulose Substances 0.000 description 1
- 235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000004245 medial forebrain bundle Anatomy 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- -1 monosulfate Chemical compound 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 210000002970 posterior hypothalamus Anatomy 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002582 psychostimulating effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/751,830 US4067983A (en) | 1976-12-17 | 1976-12-17 | Pharmaceutical compositions and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1560247A true GB1560247A (en) | 1980-01-30 |
Family
ID=25023676
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB51442/77A Expired GB1560247A (en) | 1976-12-17 | 1977-12-09 | Pharmaceutical compositions |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US4067983A (cg-RX-API-DMAC10.html) |
| JP (1) | JPS5953884B2 (cg-RX-API-DMAC10.html) |
| AU (1) | AU514828B2 (cg-RX-API-DMAC10.html) |
| BE (1) | BE861648A (cg-RX-API-DMAC10.html) |
| CA (1) | CA1087987A (cg-RX-API-DMAC10.html) |
| DE (1) | DE2755017A1 (cg-RX-API-DMAC10.html) |
| FR (1) | FR2374036A1 (cg-RX-API-DMAC10.html) |
| GB (1) | GB1560247A (cg-RX-API-DMAC10.html) |
| HK (1) | HK3984A (cg-RX-API-DMAC10.html) |
| IL (1) | IL53578A (cg-RX-API-DMAC10.html) |
| NZ (1) | NZ185928A (cg-RX-API-DMAC10.html) |
| PH (1) | PH13130A (cg-RX-API-DMAC10.html) |
| ZA (1) | ZA777358B (cg-RX-API-DMAC10.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4371537A (en) * | 1981-08-13 | 1983-02-01 | The Dow Chemical Company | Sulfur-substituted phenoxypyridines having antiviral activity |
| US4434169A (en) | 1983-01-03 | 1984-02-28 | Warner-Lambert Company | Pharmaceutical compositions and methods |
| US4666926A (en) * | 1986-02-27 | 1987-05-19 | Warner-Lambert Company | Transdermal formulations |
| US5232934A (en) * | 1992-07-17 | 1993-08-03 | Warner-Lambert Co. | Method for the treatment of psychomotor stimulant addiction |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH434868A (de) * | 1964-02-10 | 1967-04-30 | Ciba Geigy | Schädlingsbekämpfungsmittel |
-
1976
- 1976-12-17 US US05/751,830 patent/US4067983A/en not_active Expired - Lifetime
-
1977
- 1977-12-08 BE BE183290A patent/BE861648A/xx not_active IP Right Cessation
- 1977-12-09 JP JP52147322A patent/JPS5953884B2/ja not_active Expired
- 1977-12-09 PH PH20533A patent/PH13130A/en unknown
- 1977-12-09 FR FR7737158A patent/FR2374036A1/fr active Granted
- 1977-12-09 CA CA292,755A patent/CA1087987A/en not_active Expired
- 1977-12-09 NZ NZ185928A patent/NZ185928A/en unknown
- 1977-12-09 ZA ZA00777358A patent/ZA777358B/xx unknown
- 1977-12-09 IL IL53578A patent/IL53578A/xx unknown
- 1977-12-09 DE DE19772755017 patent/DE2755017A1/de active Granted
- 1977-12-09 AU AU31415/77A patent/AU514828B2/en not_active Expired
- 1977-12-09 GB GB51442/77A patent/GB1560247A/en not_active Expired
-
1984
- 1984-01-12 HK HK39/84A patent/HK3984A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FR2374036A1 (fr) | 1978-07-13 |
| ZA777358B (en) | 1979-07-25 |
| JPS5953884B2 (ja) | 1984-12-27 |
| NZ185928A (en) | 1984-05-31 |
| CA1087987A (en) | 1980-10-21 |
| AU3141577A (en) | 1979-06-14 |
| JPS5379038A (en) | 1978-07-13 |
| BE861648A (fr) | 1978-03-31 |
| DE2755017C2 (cg-RX-API-DMAC10.html) | 1988-02-04 |
| IL53578A0 (en) | 1978-03-10 |
| HK3984A (en) | 1984-01-20 |
| US4067983A (en) | 1978-01-10 |
| DE2755017A1 (de) | 1978-06-29 |
| IL53578A (en) | 1980-11-30 |
| PH13130A (en) | 1979-12-12 |
| AU514828B2 (en) | 1981-02-26 |
| FR2374036B1 (cg-RX-API-DMAC10.html) | 1980-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5232934A (en) | Method for the treatment of psychomotor stimulant addiction | |
| EP0339280A2 (en) | Use of N,N-dimethyl-1-(1-(4-chlorophenyl)cyclobutyl)-3-methylbutylamine for treatment of cerebral disorders | |
| EP0077372A1 (de) | NEUE PYRAZOLO(3,4-d)PYRIMIDINE, VERFAHREN ZU DEREN HERSTELLUNG UND SIE ENTHALTENDE ARZNEIMITTEL | |
| EP0278161B1 (en) | Ketone derivatives as medicaments for the treatment or prevention of the withdrawal syndrome | |
| PL115958B1 (en) | Process for preparing novel 1-/p-methoxybenzoyl/-2-pyrolydinone | |
| JPH0354922B2 (cg-RX-API-DMAC10.html) | ||
| US4067983A (en) | Pharmaceutical compositions and methods | |
| US5789407A (en) | Method of treating depression with certain triazine derivatives | |
| EP4146214A1 (en) | Use of dopamine d3 partial agonists for treating central nervous system disorders | |
| RU2073678C1 (ru) | (s)-1-[(10-хлор-6,7-дигидро-4-оксо-3-фенил-4h-бензо/а/хинолизин-1-ил)карбонил]-3-этоксипирролидин, (s)-1-[(10-хлор-6,7-дигидро-4-оксо-3-фенил-4h-бензо/а/хинолизин-1-ил)карбонил]-3-оксипирролидин в качестве промежуточного продукта, композиция, обладающая гипнотическим неседативным действием | |
| EA002719B1 (ru) | Новые соли с полезными органолептическими свойствами | |
| WO1988007043A1 (en) | Pharmacologically active cholinergic compositions, and methods for making same and use thereof in treating disease | |
| NZ204072A (en) | Pharmaceutical compositions which contain theophylline as active ingredient | |
| DE1770135A1 (de) | Verfahren zur Herstellung von 2,4-Benzdiazepinen | |
| EA017718B1 (ru) | Новые полиморфные формы n-[4-(трифторметил)бензил]-4- метоксибутирамида | |
| EP0417637A2 (de) | Verwendung von Dopamin-Autorezeptor-Agonisten bei der Behandlung von Drogenabhängigkeit | |
| JPH0354644B2 (cg-RX-API-DMAC10.html) | ||
| HU196308B (en) | Process for producing pharmaceutical compositions containing 2-methyl-thiazolo/4,5-c/quinoline as active component | |
| US12139461B1 (en) | Piperidine compounds as PDE5 inhibitors | |
| SE502323C2 (sv) | Användning av N-(2-hydroxietyl)nikotinamidnitrat eller ett farmaceutiskt godtagbart salt därav för framställning av ett läkemedel aktivt för behandling av sjukdomar förbundna med cerebral ischemi | |
| EP4079306B1 (en) | Btk inhibitor for use in the treatment of iga nephropathy or purpura nephritis | |
| PL161161B1 (pl) | Sposób wytwarzania nowych pochodnych 2-amino-4-morfolino-6-propylo-1,3,5-trlazyny PL PL PL PL PL | |
| US3249503A (en) | Euphoriant | |
| KR100372906B1 (ko) | 뇌의 아세틸콜린 방출 증진제 | |
| JPS6344565A (ja) | Ｎ−ニコチノイルアミノ酸 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PS | Patent sealed [section 19, patents act 1949] | ||
| 732 | Registration of transactions, instruments or events in the register (sect. 32/1977) | ||
| PCNP | Patent ceased through non-payment of renewal fee |